Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder

Study Design

Observational cohort study conducted in Sweden.

Population

Sample Size: 48 participants (34 female, 14 male), Mean Age: 39.9 years (SD 10.6).

Interventions

• Experimental Group: Semaglutide (low-dose weekly injections)
• Control Group: Placebo

Primary Outcomes

Alcohol consumption, craving, and cigarette use.

Results

Semaglutide significantly reduced alcohol consumption, drinks per drinking day, and weekly alcohol craving compared to placebo. It also showed a greater reduction in heavy drinking days over time.

Conclusion

GLP-1 agonists, especially semaglutide, may help reduce alcohol consumption and cravings. Further clinical trials are needed to confirm these findings.

Study Results (Semaglutide vs Placebo)